Bioceres Q4 EPS $(0.50) misses $(0.06) estimate; sales miss
- Bioceres Q4 EPS of $(0.50) missed the $(0.06) estimate by 733%
- Quarterly sales of $55.9 million missed the $79.0 million consensus
- Sales declined 25.17% YoY from $74.7 million in the prior period
- Adjusted EBITDA turned positive at $0.6 million despite revenue pressure
- Full year FY26 revenue declined 18% to $238.3 million
*this image is generated using AI for illustrative purposes only.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) reported fourth-quarter losses of $(0.50) per share, missing the analyst consensus estimate of $(0.06) by 733.33 percent. Quarterly sales of $55.9 million also missed the $79.0 million estimate by 29.24 percent.
The per-share loss represents a 34.21 percent increase over the $(0.76) loss recorded in the same period last year. Revenue declined 25.17 percent year-over-year from $74.7 million in the prior-year quarter.
Financial Highlights
Total revenues for 4Q26 were $55.9 million, broadly unchanged from the prior-year quarter figure of $55.4 million reported in previous filings, though the new data indicates a 25.17 percent decrease from $74.7 million. For the full fiscal year 2026, revenues declined 18% to $238.3 million.
| Metric | 4Q25 | 4Q26 | Change | FY25 | FY26 | Change |
|---|---|---|---|---|---|---|
| Total Revenue | $55.4 million | $55.9 million | +1% | $289.4 million | $238.3 million | -18% |
| Gross Profit | $13.6 million | $12.7 million | -6% | $105.0 million | $82.9 million | -21% |
| Operating Expenses | $28.5 million | $23.9 million | -16% | $103.2 million | $82.3 million | -20% |
| Net Loss (Continuing) | ($54.4) million | ($31.8) million | -42% | ($49.1) million | ($54.4) million | +11% |
| Adjusted EBITDA | ($9.6) million | $0.6 million | N/M | $28.9 million | $25.5 million | -12% |
Note: All figures in millions of U.S. dollars. Net loss values shown in parentheses.
Segment Performance
Revenue stability in the fourth quarter was supported by strong growth in Crop Nutrition, which rose 36% year-over-year to $23.5 million. This growth offset declines in other segments:
- Crop Protection: Revenues fell 7% to $27.7 million.
- Seed and Integrated Products: Revenues dropped 43% to $4.8 million, reflecting the substantially completed reconfiguration of the Seeds business.
For the full year, Crop Nutrition revenues remained flat at $77.0 million, while Crop Protection declined 16% to $123.7 million and Seed and Integrated Products fell 41% to $37.7 million.
What the Numbers Show
The divergence between gross profit and operating expense trends highlights the impact of management's restructuring efforts. While gross profit declined 6% in the quarter—partly masked by a $4.0 million non-recurring inventory adjustment for obsolescence—SG&A expenses fell sharply by 19% ($4.9 million reduction). This disproportionate reduction in operating costs relative to revenue pressure allowed the company to flip Adjusted EBITDA from negative $9.6 million to positive $0.6 million, marking a return to operational cash generation from continuing operations.
Management Commentary
Federico Trucco, Chairman & CEO, noted that fiscal 2026 was challenging due to ongoing litigation with creditors, which led to the foreclosure auction of the Pro Farm Group (PFG) business. PFG has been classified as discontinued operations. Trucco emphasized that the company has focused on core capabilities, reducing its cost structure, and strengthening operating discipline. He stated that the nearly two-year reconfiguration of the Seed business is now substantially complete, providing a clear roadmap for rationalizing the portfolio and aligning R&D investments with financial objectives.
Conference Call Details
Bioceres will host a conference call on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time to discuss these results. The session will be led by Chairman & CEO Federico Trucco, CFO Ezequiel Simmermacher, and Head of Investor Relations Paula Savanti.
| Detail | Information |
|---|---|
| Date | Tuesday, September 15, 2026 |
| Time | 8:30 a.m. ET, 5:30 a.m. PT |
| US Toll Free | 1 833-461-5787 |
| Meeting ID | 858 577 061 |
Participants are advised to dial in 5-10 minutes prior to registration. The call will be broadcast live and available for replay on the company’s investor relations website.
How will the completion of the Seed business reconfiguration impact Bioceres' R&D pipeline and future product launches in the coming fiscal year?
What specific strategies is management implementing to reverse the 16% decline in Crop Protection revenues amid competitive market pressures?
Given the recent foreclosure of the Pro Farm Group, what is the timeline for fully integrating discontinued operations into the financial statements and resolving remaining creditor litigation?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
